VEGFA and diabetic retinopathy: In 2004, the U.S. Food and Drug Administration (FDA) approved pegaptanib sodium for the treatment of age-related macular degeneration, in which abnormal VEGF signals are associated with abnormal angiogenesis and edema in the retina, similar to diabetic retinopathy [21].